/
Gastroenterology
Inflammatory Bowel Disease
42
Pipeline Programs↗
57
Active Trials↗
21
Companies Involved↗
Inflammatory Bowel Disease is a moderately active landscape with 42 programs across 21 companies. The most active players are Mirador Therapeutics, Inc., AbbVie, Bristol-Myers Squibb. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical32
Phase 15
Phase 24
Phase 31
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
31 of 35 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 100% of 42 pipeline programs.
Analysis
Trial Status
173
clinical trials
Completed73 · 42%
Unknown status29 · 17%
Not yet recruiting27 · 16%
Recruiting26 · 15%
Terminated9 · 5%
Withdrawn5 · 3%
Other4 · 2%
Clinical Trials
Trial Activity
173 trials
Fermented Vegan Optimized Diet in Health and Colitis
Recruiting·—·Preclinical·NCT06696222·240 enrolled
Vitamin B6 Aids in Treating Inflammatory Bowel Disease
Recruiting·—·N/A·NCT06512441·220 enrolled
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
Recruiting·—·N/A·NCT06780683·174 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)